Privitera, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 253
EU - Europa 151
AS - Asia 56
AF - Africa 1
Totale 461
Nazione #
US - Stati Uniti d'America 251
SE - Svezia 62
IT - Italia 33
SG - Singapore 25
CN - Cina 17
IE - Irlanda 17
FR - Francia 16
ID - Indonesia 10
DE - Germania 5
GB - Regno Unito 3
AT - Austria 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
IN - India 2
BE - Belgio 1
CA - Canada 1
CI - Costa d'Avorio 1
ES - Italia 1
FI - Finlandia 1
HK - Hong Kong 1
HR - Croazia 1
IR - Iran 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 461
Città #
Chandler 101
New York 23
Singapore 21
Dublin 17
Marseille 12
Ashburn 11
Boston 10
Jakarta 10
Princeton 10
Milan 9
Rome 6
Guasila 4
Beijing 3
Los Angeles 3
San Mateo 3
Seattle 3
Shenyang 3
Brno 2
Cagliari 2
Houston 2
Leawood 2
Miami 2
Portocannone 2
Sacramento 2
Sofia 2
Vienna 2
Wilmington 2
Abidjan 1
Boardman 1
Bremen 1
Brussels 1
Castellammare del Golfo 1
Cattolica 1
Central 1
Changsha 1
Charlotte 1
Clifton 1
Dearborn 1
Duncan 1
Frankfurt am Main 1
Hanover 1
Iesi 1
Kashan 1
Krimpen Aan Den Ijssel 1
Lappeenranta 1
London 1
Madrid 1
Moscow 1
Mumbai 1
Munich 1
Ningbo 1
Ottawa 1
Paris 1
Warsaw 1
Woodbridge 1
Zagreb 1
Totale 298
Nome #
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 67
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 59
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 54
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 53
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 47
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 44
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 41
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 40
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 39
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 32
Totale 476
Categoria #
all - tutte 3.029
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.029


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013 0 0 0 0 0 0 0 6 1 0 6 0
2020/20212 0 0 0 0 0 0 0 0 1 0 1 0
2021/202258 1 0 0 2 0 0 0 2 0 1 23 29
2022/2023249 30 34 16 35 10 34 17 31 29 0 9 4
2023/2024116 2 33 1 9 8 21 12 3 1 2 12 12
2024/202538 1 1 17 1 18 0 0 0 0 0 0 0
Totale 476